María Rita Rodríguez-Luna1,2, Carmen Balagué2, Sonia Fernández-Ananín2, Ramon Vilallonga3, Eduardo María Targarona Soler4. 1. IRCAD, Research Institute against Digestive Cancer, France 1 Place de l'Hôpital, 67000, Strasbourg, France. 2. Gastrointestinal and Hematological Surgical Unit, Service of General and Digestive Surgery, Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona (UAB) Medical School, Carrer Sant Antoni Ma Claret, 167, 08025, Barcelona, Spain. 3. Endocrine, Metabolic and Bariatric Unit, Center of Excellence for the EAC-BC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron 119-129, 08035, Barcelona, Spain. 4. Gastrointestinal and Hematological Surgical Unit, Service of General and Digestive Surgery, Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona (UAB) Medical School, Carrer Sant Antoni Ma Claret, 167, 08025, Barcelona, Spain. etargarona@santpau.cat.
Abstract
OBJECTIVES: To review the evidence regarding the outcomes of laparoscopic techniques in cases of splenomegaly. BACKGROUND: Endoscopic approaches such as laparoscopic, hand-assisted laparoscopic, and robotic surgery are commonly used for splenectomy, but the advantages in cases of splenomegaly are controversial. REVIEW METHODS: We conducted a systematic review using PRISMA guidelines. PubMed/MEDLINE, ScienceDirect, Scopus, Cochrane Library, and Web of Science were searched up to February 2020. RESULTS: Nineteen studies were included for meta-analysis. In relation to laparoscopic splenectomy (LS) versus open splenectomy (OS), 12 studies revealed a significant reduction in length of hospital stay (LOS) of 3.3 days (p = <0.01) in the LS subgroup. Operative time was higher by 44.4 min (p < 0.01) in the LS group. Blood loss was higher in OS 146.2 cc (p = <0.01). No differences were found regarding morbimortality. The global conversion rate was 19.56%. Five studies compared LS and hand-assisted laparosocpic splenectomy (HALS), but no differences were observed in LOS, blood loss, or complications. HALS had a significantly reduced conversion rate (p < 0.01). In two studies that compared HALS and OS (n = 66), HALS showed a decrease in LOS of 4.5 days (p < 0.01) and increase of 44 min in operative time (p < 0.01), while OS had a significantly higher blood loss of 448 cc (p = 0.01). No differences were found in the complication rate. CONCLUSION: LS is a safe approach for splenomegaly, with clear clinical benefits. HALS has a lower conversion rate. Higher-quality confirmatory trials with standardized splenomegaly grading are needed before definitive recommendations can be provided. Prospero registration number: CRD42019125251.
OBJECTIVES: To review the evidence regarding the outcomes of laparoscopic techniques in cases of splenomegaly. BACKGROUND: Endoscopic approaches such as laparoscopic, hand-assisted laparoscopic, and robotic surgery are commonly used for splenectomy, but the advantages in cases of splenomegaly are controversial. REVIEW METHODS: We conducted a systematic review using PRISMA guidelines. PubMed/MEDLINE, ScienceDirect, Scopus, Cochrane Library, and Web of Science were searched up to February 2020. RESULTS: Nineteen studies were included for meta-analysis. In relation to laparoscopic splenectomy (LS) versus open splenectomy (OS), 12 studies revealed a significant reduction in length of hospital stay (LOS) of 3.3 days (p = <0.01) in the LS subgroup. Operative time was higher by 44.4 min (p < 0.01) in the LS group. Blood loss was higher in OS 146.2 cc (p = <0.01). No differences were found regarding morbimortality. The global conversion rate was 19.56%. Five studies compared LS and hand-assisted laparosocpic splenectomy (HALS), but no differences were observed in LOS, blood loss, or complications. HALS had a significantly reduced conversion rate (p < 0.01). In two studies that compared HALS and OS (n = 66), HALS showed a decrease in LOS of 4.5 days (p < 0.01) and increase of 44 min in operative time (p < 0.01), while OS had a significantly higher blood loss of 448 cc (p = 0.01). No differences were found in the complication rate. CONCLUSION: LS is a safe approach for splenomegaly, with clear clinical benefits. HALS has a lower conversion rate. Higher-quality confirmatory trials with standardized splenomegaly grading are needed before definitive recommendations can be provided. Prospero registration number: CRD42019125251.
Authors: E M Targarona; J J Espert; G Cerdán; C Balagué; J Piulachs; G Sugrañes; V Artigas; M Trias Journal: Surg Endosc Date: 1999-06 Impact factor: 4.584
Authors: G Terrosu; A Donini; U Baccarani; V Vianello; G Anania; F Zala; A Pasqualucci; F Bresadola; A Pasgualucci Journal: Surgery Date: 1998-11 Impact factor: 3.982
Authors: Ameet G Patel; Jane E Parker; Ben Wallwork; Keith B Kau; Nora Donaldson; Michael R Rhodes; Nicholas O'Rourke; Les Nathanson; George Fielding Journal: Ann Surg Date: 2003-08 Impact factor: 12.969
Authors: Abdulmalik M S Altaf; Mark Sawatzky; James Ellsmere; Hendrik Jaap Bonjer; Steven Burrell; Robert Abraham; Stephen Couban; Dennis Klassen Journal: Surg Endosc Date: 2009-01-23 Impact factor: 4.584
Authors: T Vowinkel; F Becker; A S Mehdorn; A K Schwieters; W A Mardin; N Senninger; B Strücker; A Pascher Journal: Langenbecks Arch Surg Date: 2022-05-04 Impact factor: 2.895